Clinical trials: Metabolic Dysfunction-Associated Liver Disease
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Children
Screening and Intervention of MASLD in Children
Non-alcoholic fatty liver disease (NAFLD) in children and adolescents has recently been renamed metabolic dysfunction-associated steatotic liver disease (MASLD).
- Trial name
- NCT06905795
- Testing
- Fibroscan test, Nutrition guidance, Increase physical activity
- Where
- China
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Ningbo No. 1 Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease
Effects of Short-term Perioperative Daidzein Intervention on Liver Histopathology in Patients With MASLD
This clinical trial aims to learn whether daidzein can improve liver tissue changes in adults with metabolic dysfunction-associated steatotic liver disease, also called MASLD.
- Trial name
- DAIMAS (NCT07623044)
- Testing
- Daidzein
- Volunteers
- 44 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Metabolic-dysfunction Associated Liver Disease (MASLD)
Testing a Multilevel, Culturally Appropriate Lifestyle Intervention For Hispanic Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
The purpose of this study is to understand if a behavioral lifestyle intervention called the Healthy Liver/Hígado Sano program can help Hispanic/Latino patients with metabolic dysfunction associated steatotic liver disease…
- Trial name
- NCT07199491
- Testing
- Healthy Liver/Hígado Sano program, Usual Care
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- The University of Texas Health Science Center, Houston
Fatty Liver, NAFLD
Effect of CoQ10 on the Outcome of MAFLD Patients
So far there has been no universal treatment for MAFLD since it has a complex etiology that involves ethnic, genetic, metabolic and environmental factors.
- Trial name
- NCT05984745
- Testing
- Coenzyme Q10 Forte® capsules
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called MASH. In this study, researchers are looking at the effect of ALN-CIDEB on reducing liver fat, liver…
- Trial name
- NCT07631637
- Testing
- ALN-CIDEB
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- Regeneron Pharmaceuticals
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Steato-Hepatitis (NASH)
How Abnormal Function of Fat Tissue in Type 1 Diabetes Contributes to Fat in the Liver
Steatotic liver disease associated with metabolic dysfunction (MASLD) is a disease caused by excess fat storage in the liver. Excessive fat delivery to the liver and MASLD typically occurs in people with abdominal obesity and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Steato-Hepatitis (NASH), Type 1 Diabetes Mellitus
- Trial name
- AGL14 (NCT07133854)
- Testing
- Imaging PET/MRI, Stable isotope infusions, meal test
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Université de Sherbrooke
Metabolic Dysfunction-Associated Steatotic Liver Disease
Clinical Profile of Patients With MASLD in Kazakhstan and Clinical Effectiveness of Ursosan in Almaty
This study will look at the health characteristics of adults with metabolic dysfunction-associated steatotic liver disease (MASLD) in Kazakhstan.
- Trial name
- NCT07889999
- Where
- 7 sites in Kazakhstan
- Volunteers
- 420 people
- Sponsor
- Kazakh Association of Internal Medicine Specialists
Transient Elastography, MASLD
Hepatic Elastography-Enhanced Lifestyle Modification in MASLD
The 2022 National Health Survey in Thailand revealed a substantial rise in obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).
- Conditions
- Transient Elastography, MASLD, BMI, Metabolic Syndrome
- Trial name
- NCT06826807
- Testing
- Regular monitoring with transient elastography
- Where
- Thailand
- Volunteers
- 92 people
- Sponsor
- Mahidol University
Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD)
Time-restricted Feeding in MASLD
The recommended treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) currently focuses on lifestyle changes, including dietary adjustments and increased physical activity.
- Trial name
- MASLD-Interval (NCT07530809)
- Testing
- time-restricted feeding in a 5:2 regimen
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Universität des Saarlandes
Metabolic-dysfunction Associated Steatotic Liver Disease
SMART Diets for MASLD
This phase 2 trial is a single-site sequential, multiple assignment, randomized trial (SMART) to test and construct a high-quality adaptive intervention of essential amino acids (EAA) and/or Low Sugar Diet for children with…
- Trial name
- NCT07459504
- Testing
- Essential Amino Acids Supplementation intervention, Low sugar diet
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Michigan State University
MASLD, Pediatric
Ultrasound-Based Estimation of Hepatic Steatosis in Pediatric MASLD
The purpose of this study is to validate an artificial intelligence (AI)-based algorithm that estimates hepatic steatosis using ultrasound (US) B-mode images in pediatric participants with metabolic dysfunction-associated…
- Trial name
- NCT07265011
- Testing
- Ultrasound and MRI
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Jae Won Choi
Metabolic Dysfunction Associated Steatotic Liver Disease, Overweight (BMI > 25)
Feasibility of the Paso Program for Patients With Metabolic Dysfunction Associated Steatotic Liver Disease
The purpose of this study is to learn whether the Paso weight loss program is feasible for Mexican and Central American patients with fatty liver disease.
- Conditions
- Metabolic Dysfunction Associated Steatotic Liver Disease, Overweight (BMI > 25), Metabolic Syndrome
- Trial name
- NCT06854185
- Testing
- Paso Program
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Baylor College of Medicine
Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Evaluating the Pharmacokinetics and Safety of Miricorilant
A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
- Trial name
- NCT07553663
- Testing
- Miricorilant
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Corcept Therapeutics
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) & Steatohepatitis (MASH)
A Real-world Assessment in Implementation of the MASH Patient Care Pathway in Chinese Population Using the Meinian Health Check-up Database
The primary objective of this study is to estimate the proportion of people with low/intermediate/high risk of advanced fibrosis in at risk Chinese population based on the European Association for the Study of the Liver (EASL)…
- Trial name
- IMPACT MASH (NCT06741111)
- Testing
- No treatment given
- Where
- India
- Volunteers
- 1,233,970 people
- Sponsor
- Novo Nordisk A/S
Thyroid Dysfunction, Metabolic Dysfunction-Associated Fatty Liver Disease
Thyroid Dysfunction and Its Association With Metabolic Dysfunction-Associated Fatty Liver Disease
This study aims to evaluate the prevalence of thyroid dysfunction and its association with metabolic dysfunction-associated fatty liver disease.
- Trial name
- NCT06739330
- Testing
- Fibroscan
- Where
- Egypt
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tanta University
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Alcohol-Related Liver Disease
A Large Language Model-based Chatbot for Alcohol Reduction in Patients With Metabolic Alcohol-Related Liver Disease
The goal of this pilot randomized controlled trial is to evaluate the trial feasibility and acceptability of LLM-based chatbot for reducing alcohol use among patients with metabolic alcohol-related liver disease.
- Trial name
- NCT07450144
- Testing
- LLM-based chatbot, Telephone counseling, Alcohol Brief Intervention
- Where
- Hong Kong
- Volunteers
- 50 people
- Sponsor
- The University of Hong Kong
Non-Alcoholic Fatty Liver Disease, Neurocognitive Disorders
Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease
This study investigates whether a structured lifestyle program can help improve thinking skills and liver health in adults with Non-Alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT07294963
- Testing
- Structured Mediterranean Diet, Control / General Advice
- Where
- 2 sites in Pakistan
- Volunteers
- 45 people
- Sponsor
- Khyber Medical University Peshawar
MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASH With Fibrosis
Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH)
MASLD (Metabolic dysfunction-associated steatotic liver disease) is a condition where fat builds up in the liver. It is the most common cause of liver disease worldwide.
- Conditions
- MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASH With Fibrosis, Steatosis of Liver
- Trial name
- FLOURISH (NCT07013916)
- Testing
- fructose, glucose
- Where
- 2 sites in United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly
Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
This study compares the effectiveness of the dietary supplement Gepaktiv with standard medications (UDCA and Ademetionine) in patients with fatty liver disease (MAFLD) and liver enlargement (hepatomegaly).
- Conditions
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly, Nonalcoholic Fatty Liver (NAFL), Nonalcoholic Fatty Liver Disease (NAFLD)
- Trial name
- HEPACT (NCT07068191)
- Testing
- Dietary supplement "Gepaktiv", UDCA (Ursodeoxycholic acid), Ademetionine
- Where
- Russia
- Volunteers
- 90 people
- Sponsor
- Phenomen Pharma
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
UNMASK: Unveiling the Pathobiology of Metabolic Dysfunction-Associated Steatotic Liver Disease for the Discovery of Novel Therapeutics and Biomarkers
Overall design: The study will include one intervention based on Mediterranean diet plus structured lifestyle intervention (150 min/week of moderate-intensity or 75 min/week of high-intensity exercise) for a total of 16 weeks.
- Trial name
- UNMASK (NCT07652151)
- Testing
- Multimodal lifestyle intervention
- Where
- 3 sites in Italy, Spain and 1 more
- Volunteers
- 450 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla